Figure 3 - uploaded by Fatma Nur Akdogan Kittana
Content may be subject to copyright.
Correlation of Bacillales and Proteobacteria relative abundances according to stages in patient group.

Correlation of Bacillales and Proteobacteria relative abundances according to stages in patient group.

Source publication
Article
Full-text available
Copyright 2021 by Eurasian Journal of Medicine and Investigation-Available online at www.ejmi.org OPEN ACCESS This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. T he association between colon microbiota and colorec-tal cancer (CRC) has been widely investigated. Many researchers reported changes in fe...

Context in source publication

Context 1
... the subgroup analyses of patient group according to disease stage, relative abundance of Bacillales showed a negative correlation with the disease stage (r=−0.638, p≤0.001), while the abundance of Proteobacteria showed a positive correlation with disease stage (r=0.450, p=0.01) (Fig. ...

Citations

... Comparative analyses on matched stool and saliva samples from CRC patients and healthy controls showed that four bacterial species: Peptostreptococcus stomatis, Streptococcus anginosus, Solobacterium moorei, and Streptococcus koreensis were significantly abundant in oral cavity of CRC patients [26]. Similarly, another study reported a decline in the relative abundance of the Pasteurellaceae family in controls while an increase of Neisseriaceae in CRC patients [27]. On the other hand, subgroup analyses showed that with increasing stages, the relative levels of Proteobacteria increased while those of Bacillales decreased, indicating the role of these salivary microbiomes in prognostication and staging of patients [27]. ...
... Similarly, another study reported a decline in the relative abundance of the Pasteurellaceae family in controls while an increase of Neisseriaceae in CRC patients [27]. On the other hand, subgroup analyses showed that with increasing stages, the relative levels of Proteobacteria increased while those of Bacillales decreased, indicating the role of these salivary microbiomes in prognostication and staging of patients [27]. A nested case-control study on 231 CRC cases and 462 controls, suggested association of Treponema denticola, Prevotella intermedia, Actinobacteria, Bifidobacteriace ae,Bacteroidetes, Prevotella denticola and Prevotella sp. ...
Article
Full-text available
Colorectal cancer (CRC) is one of the most common cancers worldwide. The diagnosis, prognosis and therapeutic monitoring of CRC depends largely on tissue biopsy. However, due to tumor heterogeneity and limitations such as invasiveness, high cost and limited applicability in longitudinal monitoring, liquid biopsy has gathered immense attention in CRC. Liquid biopsy has several advantages over tissue biopsy including ease of sampling, effective monitoring, and longitudinal assessment of treatment dynamics. Furthermore, the importance of liquid biopsy is signified by approval of several liquid biopsy assays by regulatory bodies indicating the powerful approach of liquid biopsy for comprehensive CRC screening, diagnostic and prognostics. Several liquid biopsy biomarkers such as novel components of the microbiome, non-coding RNAs, extracellular vesicles and circulating tumor DNA are extensively being researched for their role in CRC management. Majority of these components have shown promising results on their clinical application in CRC including early detection, observe tumor heterogeneity for treatment and response, prediction of metastases and relapse and detection of minimal residual disease. Therefore, in this review, we aim to provide updated information on various novel liquid biopsy markers such as a) oral microbiota related bacterial network b) gut microbiome-associated serum metabolites c) PIWI-interacting RNAs (piRNAs), microRNA(miRNAs), Long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and d) circulating tumor DNAs (ctDNA) and circulating tumor cells (CTC) for their role in disease diagnosis, prognosis, treatment monitoring and their applicability for personalized management of CRC.